STOCK TITAN

scPharmaceuticals Inc. - SCPH STOCK NEWS

Welcome to our dedicated page for scPharmaceuticals news (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on scPharmaceuticals stock.

scPharmaceuticals Inc. (NASDAQ: SCPH) is a clinical-stage pharmaceutical company dedicated to revolutionizing the administration of infused therapies. Headquartered in Burlington, MA, the company is spearheading advancements in patient care through its proprietary platform that enables subcutaneous administration of treatments traditionally limited to intravenous (IV) delivery. This innovative approach aims not only to improve patient outcomes but also to significantly reduce healthcare costs.

The company’s flagship product, Furoscix, is a patented furosemide formulation designed for subcutaneous use via the wearable, portable sc2Wear Infusor. Furoscix targets the treatment of edema in heart failure patients, offering them a convenient and effective alternative to traditional IV therapies. With a focus on self-administration, scPharmaceuticals is paving the way for outpatient care of acute conditions.

Recent achievements have bolstered scPharmaceuticals’ position in the pharmaceutical landscape. The company generated $6.1 million in product revenue for the first quarter of 2024, a marked increase from $2.1 million in the same period of the previous year. This growth reflects the rising demand for Furoscix and the successful execution of their commercial strategy.

Moreover, scPharmaceuticals is actively pursuing long-term growth initiatives for Furoscix. These include expanding its indication to include NYHA Class IV heart failure patients and chronic kidney disease, both pending FDA review. Another promising development is the initiation of a pharmacokinetic study to support a low-volume auto-injector version of Furoscix, aimed at providing greater flexibility in treatment options.

The company’s financial health remains robust, with strategic investments in research and development, as well as selling, general, and administrative expenses to support its growth trajectory. Despite reporting a net loss of $14.1 million for the first quarter of 2024, compared to $11.2 million for the first quarter of 2023, scPharmaceuticals remains focused on driving forward with its innovative solutions and strategic partnerships.

For more information, please visit www.scPharmaceuticals.com.

Rhea-AI Summary

scPharmaceuticals (SCPH) reported strong preliminary Q4 2024 results, with expected net revenue between $12-12.3 million, representing 99% growth over Q4 2023. The company's full-year 2024 net revenue is anticipated to reach $36.2-36.5 million, up 167% from 2023's $13.6 million.

Q4 2024 highlights include approximately 13,300 FUROSCIX doses shipped, a 23% increase from Q3's 10,800 doses. The gross-to-net discount is expected to be 18-19%, compared to 15.7% in Q3 2024. The company ended 2024 with approximately $75.7 million in cash and cash equivalents, with accounts receivable increasing 27% from September 2024.

SCPH expanded its distribution network by adding a specialty pharmacy and anticipates growth in 2025 through Medicare redesign implementation and a potential FUROSCIX indication expansion for chronic kidney disease patients in March.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
-
Rhea-AI Summary

scPharmaceuticals reported strong Q3 2024 results with FUROSCIX net revenue of $10.0 million, up 164% from Q3 2023 and 24% from Q2 2024. Key achievements include FDA approval for NYHA Class IV patients, positive PK/PD data for Autoinjector program, and completion of $175 million financing. The company filled approximately 10,800 FUROSCIX doses (+16% QoQ) and expanded to 3,100 unique prescribers. However, gross-to-net discount increased to 15.7% from 8% in Q2. The company reported a net loss of $35.1 million ($0.75 per share), with $91.5 million cash on hand as of quarter-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.07%
Tags
-
Rhea-AI Summary

scPharmaceuticals (Nasdaq: SCPH) announced it will release its third quarter 2024 financial results on Wednesday, November 13, 2024. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss financial results and provide a business update. Participants can join via phone using domestic (1-877-407-9208) or international (1-201-493-6784) numbers with conference code 13749995. A webcast and replay will be available through the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
Rhea-AI Summary

scPharmaceuticals Inc. (Nasdaq: SCPH) has announced a Key Opinion Leader (KOL) webinar scheduled for October 22, 2024, at 1:00 PM ET. The webinar will focus on a nephrologist's perspective on using FUROSCIX for treating fluid overload in heart failure and its potential use in chronic kidney disease (CKD) patients.

The event will feature Dr. Michael Aaronson from Lincoln Nephrology and Hypertension. The FDA has set a PDUFA target action date of March 6, 2025, for scPharmaceuticals' Supplemental New Drug Application (sNDA) to expand FUROSCIX's indication to include CKD-related fluid overload treatment.

scPharmaceuticals' management will provide updates on long-term growth initiatives, including the FDA-approved expansion of FUROSCIX for NYHA Class IV heart failure patients and the development of a low volume autoinjector. A live Q&A session will follow the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
conferences
-
Rhea-AI Summary

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company specializing in optimized delivery of infused therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. John Tucker, the company's President & CEO, is scheduled to present on Wednesday, September 11 at 10:00AM ET.

In addition to the presentation, Mr. Tucker will be engaging in investor meetings throughout the day. Interested parties can access a webcast of the presentation via a provided link or through the 'News & Events' section of scPharmaceuticals' official website.

This event provides an opportunity for scPharmaceuticals to showcase its progress in developing products aimed at advancing patient care and reducing healthcare costs through innovative infusion therapy delivery methods.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
conferences
-
Rhea-AI Summary

scPharmaceuticals Inc. (Nasdaq: SCPH) reported strong Q2 2024 financial results and business updates. Key highlights include:

- Net FUROSCIX revenue of $8.1 million, up 33% sequentially from Q1
- Approximately 9,300 FUROSCIX doses filled, a 15% increase from Q1
- Completed financings of up to $175 million, extending cash runway through expected profitability
- FDA approval to expand FUROSCIX indication for NYHA Class IV chronic heart failure patients
- Positive topline PK/PD data for FUROSCIX autoinjector
- FDA acceptance of sNDA for FUROSCIX label expansion to include CKD patients

The company's focus on commercial growth and lifecycle management initiatives positions FUROSCIX as a key part of a new heart failure treatment paradigm.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

scPharmaceuticals Inc. (Nasdaq: SCPH) has announced the pricing of a public offering of 12,000,000 shares of common stock at $4.00 per share and pre-funded warrants for up to 500,000 shares at $3.999 per underlying share. The offering aims to raise approximately $50.0 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase up to an additional 1,875,000 shares. The offering, expected to close on August 13, 2024, is being made pursuant to a shelf registration statement. Leerink Partners and TD Cowen are acting as joint book-running managers, with Craig-Hallum as lead manager and Maxim as manager.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

scPharmaceuticals Inc. (SCPH) has secured non-dilutive financings totaling up to $125 million with Perceptive Advisors. The deal includes a $75 million senior secured loan and a $50 million revenue interest financing. Key benefits include:

1. Refinancing of existing debt with improved terms
2. Lower interest rate and extended interest-only period
3. Reduced minimum cash requirement to $5 million
4. Additional funding for FUROSCIX commercialization

The revenue interest financing involves tiered single-digit royalties on FUROSCIX global net sales, capped at 1.6x to 2.0x the purchase price. This partnership aims to support FUROSCIX's potential in reducing unnecessary hospital utilization for heart failure patients while generating cost savings for healthcare payers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

scPharmaceuticals (Nasdaq: SCPH) announced FDA approval of its Supplemental New Drug Application for FUROSCIX, expanding its indication to include NYHA Class IV chronic heart failure patients. This expansion covers the most symptomatic patients with the greatest limitation on physical activity, representing about 10% of all heart failure patients nationally.

FUROSCIX is now indicated for treating congestion due to fluid overload in adult patients with chronic heart failure, regardless of NYHA functional class. This approval builds on FUROSCIX's established efficacy and safety profile, potentially preventing heart failure-related hospital admissions or readmissions.

The company views this expansion as a foundation for driving sustained long-term growth, complementing the growing adoption of FUROSCIX among cardiologists and heart failure specialists.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

scPharmaceuticals Inc. (SCPH) announced positive topline results from a pharmacokinetic study of SCP-111, an investigational furosemide autoinjector. The study achieved its primary and secondary endpoints, demonstrating 107.3% bioavailability compared to IV furosemide. SCP-111 showed similar urine output and electrolyte excretion to IV furosemide, with minimal pain reported at injection sites. The company aims to submit a Supplemental New Drug Application (sNDA) to the FDA by year-end 2024.

The study involved 21 healthy volunteers aged 45-80 in a randomized, two-way crossover design. If approved, SCP-111 could provide an alternative to the current FUROSCIX on-body infusor, potentially offering greater treatment flexibility for cardiologists and heart failure patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of scPharmaceuticals (SCPH)?

The current stock price of scPharmaceuticals (SCPH) is $3.5 as of January 15, 2025.

What is the market cap of scPharmaceuticals (SCPH)?

The market cap of scPharmaceuticals (SCPH) is approximately 173.4M.

What is scPharmaceuticals Inc.?

scPharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on developing subcutaneous administration therapies to improve patient care and reduce healthcare costs.

What is Furoscix?

Furoscix is scPharmaceuticals' patented formulation of furosemide for subcutaneous administration, aimed at treating edema in heart failure patients.

Where is scPharmaceuticals headquartered?

scPharmaceuticals is headquartered in Burlington, MA.

How much revenue did scPharmaceuticals generate in Q1 2024?

scPharmaceuticals generated $6.1 million in product revenue in the first quarter of 2024.

What are the future plans for Furoscix?

Future plans include expanding Furoscix's indication to NYHA Class IV heart failure and chronic kidney disease, pending FDA approval, and developing a low-volume auto-injector version.

What are the benefits of scPharmaceuticals' platform?

The platform enables subcutaneous administration of therapies, improving patient care and reducing healthcare costs by offering convenient alternatives to IV treatments.

What recent financial results did scPharmaceuticals report?

For Q1 2024, scPharmaceuticals reported a net loss of $14.1 million, with increased revenues and expenses due to commercial rollout and development costs.

What is the sc2Wear Infusor?

The sc2Wear Infusor is a wearable, portable device developed by scPharmaceuticals for the subcutaneous administration of Furoscix.

Who are the key contacts for more information?

For more information, contact Katherine Miranda at scPharmaceuticals (781-301-6869, kmiranda@scpharma.com) or PJ Kelleher at LifeSci Advisors (617-430-7579, pkelleher@lifesciadvisors.com).

What is scPharmaceuticals' approach to outpatient care?

scPharmaceuticals focuses on developing solutions for the subcutaneous, self-administration of IV-strength treatments, advancing outpatient care for acute conditions.
scPharmaceuticals Inc.

Nasdaq:SCPH

SCPH Rankings

SCPH Stock Data

173.39M
35.60M
10.68%
81.64%
11.83%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BURLINGTON